Royal Bank of Canada started coverage on shares of Genmab A/S (NASDAQ:GMAB) in a report issued on Monday, BenzingaRatingsTable reports. The firm issued an outperform rating and a $23.00 target price on the stock.
Separately, Morgan Stanley began coverage on shares of Genmab A/S in a research note on Monday. They set an overweight rating on the stock.
NASDAQ GMAB opened at $19.89 on Monday. Genmab A/S has a one year low of $12.10 and a one year high of $21.45.
Genmab A/S Company Profile
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
Further Reading: How can investors benefit from after-hours trading?
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.